Shattuck Labs Announces Orphan Drug Designation Granted by the U.S. Food and Drug Administration (FDA) for SL-172154 for the Treatment of Acute Myeloid Leukemia (AML)

June 10, 2024

https://www.globenewswire.com/news-release/2024/06/10/2895899/0/en/Shattuck-Labs-Announces-Orphan-Drug-Designation-Granted-by-the-U-S-Food-and-Drug-Administration-FDA-for-SL-172154-for-the-Treatment-of-Acute-Myeloid-Leukemia-AML.html

AUSTIN, TX and DURHAM, NC, June 10, 2024 (GLOBE NEWSWIRE) — Shattuck Labs, Inc. (Shattuck) (Nasdaq:STTK), a clinical-stage biotechnology company pioneering the development of bifunctional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that the U.S. FDA has granted orphan drug designation (ODD) to lead clinical candidate SL-172154 for the treatment of AML.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.